BACKGROUND: The role of reduced intensity conditioning allogeneic stem transplantation (RICalloSCT) in the management of patients with Hodgkin's lymphoma remains controversial. DESIGN AND METHODS: To further define its role we have conducted a retrospective analysis of 285 patients with HL who underwent a RICalloSCT in order to identify prognostic factors that predict outcome. Eighty percent of patients had undergone a prior autologous stem cell transplantation and 25% had refractory disease at transplant. RESULTS: Non-relapse mortality was associated with chemorefractory disease, poor performance status, age >45 and transplantation before 2002. For patients with no risk factors the 3-year non-relapse mortality rate was 12.5% compared to 46.2% for patients with 2 or more risk factors. The use of an unrelated donor had no adverse effect on the non-relapse mortality. Acute graft versus host disease (aGVHD) grades II-IV developed in 30% and chronic GVHD in 42%. The development of cGVHD was associated with a lower relapse rate. The disease progression rate at one and five years was 41% and 58.7% respectively and was associated with chemorefractory disease and extent of prior therapy. Donor lymphocyte infusions were administered to 64 patients for active disease of whom 32% showed a clinical response. Eight out of 18 patients receiving donor lymphocyte infusions alone had clinical responses. Progression-free and overall survival were both associated with performance status and disease status at transplant. Patients with neither risk factor had a 3-year PFS and overall survival of 42% and 56% respectively compared to 8% and 25% for patients with one or more risk factors. Relapse within six months of a prior autologous transplant was associated with a higher relapse rate and a lower progression-free. CONCLUSIONS: This analysis identifies important clinical parameters that may be useful in predicting the outcome of RICaIICalloSCT in Hodgkin's lymphoma.
BACKGROUND: The role of reduced intensity conditioning allogeneic stem transplantation (RICalloSCT) in the management of patients with Hodgkin's lymphoma remains controversial. DESIGN AND METHODS: To further define its role we have conducted a retrospective analysis of 285 patients with HL who underwent a RICalloSCT in order to identify prognostic factors that predict outcome. Eighty percent of patients had undergone a prior autologous stem cell transplantation and 25% had refractory disease at transplant. RESULTS: Non-relapse mortality was associated with chemorefractory disease, poor performance status, age >45 and transplantation before 2002. For patients with no risk factors the 3-year non-relapse mortality rate was 12.5% compared to 46.2% for patients with 2 or more risk factors. The use of an unrelated donor had no adverse effect on the non-relapse mortality. Acute graft versus host disease (aGVHD) grades II-IV developed in 30% and chronic GVHD in 42%. The development of cGVHD was associated with a lower relapse rate. The disease progression rate at one and five years was 41% and 58.7% respectively and was associated with chemorefractory disease and extent of prior therapy. Donor lymphocyte infusions were administered to 64 patients for active disease of whom 32% showed a clinical response. Eight out of 18 patients receiving donor lymphocyte infusions alone had clinical responses. Progression-free and overall survival were both associated with performance status and disease status at transplant. Patients with neither risk factor had a 3-year PFS and overall survival of 42% and 56% respectively compared to 8% and 25% for patients with one or more risk factors. Relapse within six months of a prior autologous transplant was associated with a higher relapse rate and a lower progression-free. CONCLUSIONS: This analysis identifies important clinical parameters that may be useful in predicting the outcome of RICaIICalloSCT in Hodgkin's lymphoma.
Authors: G Akpek; R F Ambinder; S Piantadosi; R A Abrams; R A Brodsky; G B Vogelsang; M L Zahurak; D Fuller; C B Miller; S J Noga; E Fuchs; I W Flinn; P O'Donnell; E J Seifter; R B Mann; R J Jones Journal: J Clin Oncol Date: 2001-12-01 Impact factor: 44.544
Authors: A M Carella; M Cavaliere; E Lerma; R Ferrara; L Tedeschi; A Romanelli; M Vinci; G Pinotti; P Lambelet; C Loni; S Verdiani; F De Stefano; M Valbonesi; M T Corsetti Journal: J Clin Oncol Date: 2000-12-01 Impact factor: 44.544
Authors: Ronjon Chakraverty; Karl Peggs; Rajesh Chopra; Donald W Milligan; Panagiotis D Kottaridis; Stephanie Verfuerth; Johanne Geary; Dharsha Thuraisundaram; Kate Branson; Suparno Chakrabarti; Premini Mahendra; Charles Craddock; Anne Parker; Ann Hunter; Geoff Hale; Herman Waldmann; Catherine D Williams; Kwee Yong; David C Linch; Anthony H Goldstone; Stephen Mackinnon Journal: Blood Date: 2002-02-01 Impact factor: 22.113
Authors: José A Pérez-Simón; Panagiotis D Kottaridis; Rodrigo Martino; Charles Craddock; Dolores Caballero; Raj Chopra; Javier García-Conde; Don W Milligan; Stephen Schey; Alvaro Urbano-Ispizua; Anne Parker; Angel Leon; Kwee Yong; Ana Sureda; Ann Hunter; Jordi Sierra; Anthony H Goldstone; David C Linch; Jesus F San Miguel; Stephen Mackinnon Journal: Blood Date: 2002-11-01 Impact factor: 22.113
Authors: Rowena D Faulkner; Charles Craddock; Jennifer L Byrne; Prem Mahendra; Andrew P Haynes; Hugh G Prentice; Michael Potter; Antonio Pagliuca; Aloysius Ho; Stephen Devereux; Grant McQuaker; Ghulam Mufti; John Liu Yin; Nigel H Russell Journal: Blood Date: 2003-09-11 Impact factor: 22.113
Authors: Katharine Branson; Rajesh Chopra; Panagiotis D Kottaridis; Grant McQuaker; Anne Parker; Stephen Schey; Ronjon K Chakraverty; Charles Craddock; Donald W Milligan; Ruth Pettengell; Judith C W Marsh; David C Linch; Anthony H Goldstone; Catherine D Williams; Stephen Mackinnon Journal: J Clin Oncol Date: 2002-10-01 Impact factor: 44.544
Authors: K J Thomson; K S Peggs; P Smith; J Cavet; A Hunter; A Parker; R Pettengell; D Milligan; E C Morris; A H Goldstone; D C Linch; S Mackinnon Journal: Bone Marrow Transplant Date: 2008-01-14 Impact factor: 5.483
Authors: Stephen P Robinson; Anthony H Goldstone; Stephen Mackinnon; Angelo Carella; Nigel Russell; Carmen Ruiz de Elvira; Goli Taghipour; Norbert Schmitz Journal: Blood Date: 2002-08-15 Impact factor: 22.113
Authors: Paolo Anderlini; Rima Saliba; Sandra Acholonu; Grace-Julia Okoroji; Celina Ledesma; Borje S Andersson; Roy Jones; Uday R Popat; Chitra M Hosing; Yago Nieto; Muzaffar H Qazilbash; Naoto T Ueno; Sergio A Giralt; Marcos J de Lima; Richard E Champlin Journal: Leuk Lymphoma Date: 2012-01-05
Authors: Robert Chen; Joycelynne M Palmer; Sandra H Thomas; Ni-Chun Tsai; Len Farol; Auayporn Nademanee; Stephen J Forman; Ajay K Gopal Journal: Blood Date: 2012-05-18 Impact factor: 22.113
Authors: Ajay K Gopal; Robert Chen; Scott E Smith; Stephen M Ansell; Joseph D Rosenblatt; Kerry J Savage; Joseph M Connors; Andreas Engert; Emily K Larsen; Xuedong Chi; Eric L Sievers; Anas Younes Journal: Blood Date: 2014-12-22 Impact factor: 22.113
Authors: Craig S Sauter; Joanne F Chou; Esperanza B Papadopoulos; Miguel-Angel Perales; Ann A Jakubowski; James W Young; Michael Scordo; Sergio Giralt; Hugo Castro-Malaspina Journal: Leuk Lymphoma Date: 2014-03-20